Reviewing Neumora Therapeutics (NASDAQ:NMRA) & Virax Biolabs Group (NASDAQ:VRAX)

Neumora Therapeutics (NASDAQ:NMRA) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares Neumora Therapeutics and Virax Biolabs Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93 million	($1.33)	-1.26
Virax Biolabs Group	$10,000.00	134.11	-$6.06 million	N/A	N/A

Virax Biolabs Group has higher revenue and earnings than Neumora Therapeutics.

Institutional & Insider Ownership

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Neumora Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Neumora Therapeutics and Virax Biolabs Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2	1	5	1	2.56
Virax Biolabs Group	1	1	1	0	2.00

Neumora Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 359.08%. Virax Biolabs Group has a consensus price target of $1.00, indicating a potential upside of 223.62%. Given Neumora Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than Virax Biolabs Group.

Profitability

This table compares Neumora Therapeutics and Virax Biolabs Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Virax Biolabs Group	N/A	N/A	N/A

Summary

Neumora Therapeutics beats Virax Biolabs Group on 6 of the 11 factors compared between the two stocks.

About Neumora Therapeutics

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.